Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Ali, Arif N ^a,b   Ogunleye, Tomi ^a,b   Hardy, Claire W ^a,b   Shu, Hui Kuo ^a,b   Curran, Walter J ^a,b   Crocker, Ian R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

GBM; Glioblastoma multiforme; Hippocampus

Indexed keywords

BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; GLIOBLASTOMA; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; ORGANS AT RISK; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84892412279     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-20     Document Type: Article

References (46)

1. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998, 40:51-55. 10.1016/S0360-3016(97)00485-9, 9422557.
2. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
5. Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874. 10.1158/1078-0432.CCR-03-0384, 15041700.
6. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, et al. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606. 10.1093/brain/awm204, 17785346.
7. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007, 48:403-407. 10.1002/pbc.20803, 16609952.
8. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009, 73:1509-1510. 10.1212/WNL.0b013e3181bf9907, 2779003, 19884580.
9. Schmidinger M, Linzmayer L, Becherer A, Fazeny-Doerner B, Fakhrai N, Prayer D, Killer M, Ungersboeck K, Dieckmann K, Marosi C. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol 2003, 63:55-61. 10.1023/A:1023740303162, 12814255.
10. Peters KB, Reardon DA, Vredenburgh JJ, Desjardins A, Friedman HS. NC-09. Characterization of long-term survivors of primary gliblastoma multiforme and their use of psychoactive medications. Neuro Oncol 2010, 12:iv58-iv61.
11. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HWK, Pexman JHW, Fisher BJ, Gaspar LE, Cairncross JG. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994, 80:247-253. 10.3171/jns.1994.80.2.0247, 8283263.
12. Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 1980, 30:172. 10.1212/WNL.30.2.172, 6243762.
13. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990, 28:818-822. 10.1002/ana.410280614, 2178330.
14. Lieberman AN, Foo SH, Ransohoff J, Wise A, George A, Gordon W, Walker R. Long term survival among patients with malignant brain tumors. Neurosurgery 1982, 10:450-453. 10.1227/00006123-198204000-00006, 6285218.
15. Salander P, Karlsson T, Bergenheim T, Henriksson R. Long-term memory deficits in patients with malignant gliomas. J Neurooncol 1995, 25:227-238. 10.1007/BF01053156, 8592173.
16. Senger D, Cairncross JG, Forsyth PAJ. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?. Cancer J 2003, 9:214-221. 10.1097/00130404-200305000-00009, 12952306.
17. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004, 3:159-168. 10.1016/S1474-4422(04)00680-5, 14980531.
18. Drachman DA, Arbit J. Memory and the hippocampal complex. II. Is memory a multiple process?. Arch Neurol 1966, 15:52-61. 10.1001/archneur.1966.00470130056005, 5937496.
19. Levy DA, Manns JR, Hopkins RO, Gold JJ, Broadbent NJ, Squire LR. Impaired visual and odor recognition memory span in patients with hippocampal lesions. Learn Mem 2003, 10:531-536. 10.1101/lm.66703, 305469, 14657265.
20. Milner B. Disorders of learning and memory after temporal lobe lesions in man. Clin Neurosurg 1972, 19:421-446.
21. Murray EA, Mishkin M. Severe tactual memory deficits in monkeys after combined removal of the amygdala and hippocampus. Brain Res 1983, 270:340-344. 10.1016/0006-8993(83)90610-8, 6883103.
22. Murray EA, Mishkin M. Severe tactual as well as visual memory deficits follow combined removal of the amygdala and hippocampus in monkeys. J Neurosci 1984, 4:2565-2580.
23. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 1957, 20:11-21. 10.1136/jnnp.20.1.11, 497229, 13406589.
24. Moser E, Moser M, Andersen P. Spatial learning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci 1993, 13:3916-3925.
25. Malkova L, Mishkin M. One-trial memory for object-place associations after separate lesions of hippocampus and posterior parahippocampal region in the monkey. J Neurosci 2003, 23:1956-1965.
26. Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992, 99:195-231.
27. Cummings JL, Tomiyasu U, Read S, Benson DF. Amnesia with hippocampal lesions cardiopulmonary arrest. Neurology 1984, 34:679. 10.1212/WNL.34.5.679, 6538660.
28. Sidman M, Stoddard LT, Mohr JP. Some additional quantitative observations of immediate memory in a patient with bilateral hippocampal lesions. Neuropsychologia 1968, 6:245-254.
29. Mayes AR, Isaac CL, Holdstock JS, Hunkin NM, Montaldi D, Downes JJ, MacDonald C, Cezayirli E, Roberts JN. Memory for single items, word pairs, and temporal order of different kinds in a patient with selective hippocampal lesions. Cogn Neuropsychol 2001, 18:97-123.
30. Zola-Morgan S, Squire L, Amaral D. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986, 6:2950-2967.
31. Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2013, 85:348-354. 10.1016/j.ijrobp.2012.11.031, 23312272.
32. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, Khuntia D, Tome WA. Hippocampal-sparing whole-brain radiotherapy: a " how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1244-1252. 10.1016/j.ijrobp.2010.01.039, 2963699, 20598457.
33. Gondi V, Tomé WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010, 97:370-376. 10.1016/j.radonc.2010.09.013, 2997490, 20970214.
34. van Kesteren Z, Belderbos J, van Herk M, Olszewska A, Lamers E, De Ruysscher D, Damen E, van Vliet-Vroegindeweij C. A practical technique to avoid the hippocampus in prophylactic cranial irradiation for lung cancer. Radiother Oncol 2012, 102:225-227. 10.1016/j.radonc.2011.09.023, 22192478.
35. Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys 2013, 85:264-270. 10.1016/j.ijrobp.2012.02.036, 22516808.
36. McDonald MW, Shu HK, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011, 79:130-136. 10.1016/j.ijrobp.2009.10.048, 20399036.
37. RTOG 0825 - phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4664.
38. Mahajan A, Dong L, Prabhu SS, Wang C, Yongbin Z, Zhang L, Meyers C, Woo S. Application of deformable image registration to hippocampal doses and neurocognitive outcomes. Neuro Oncol 2007, 9(4):583-584.
39. Correa D. Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep 2010, 10:232-239. 10.1007/s11910-010-0108-4, 20425039.
40. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 2003, 55:992-999. 10.1016/S0360-3016(02)04205-0, 12605978.
41. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710. 10.1093/jnci/85.9.704, 8478956.
42. Bosma I, Vos MJ, Heimans JJ, Taphoorn MJB, Aaronson NK, Postma TJ, van der Ploeg HM, Muller M, Vandertop WP, Slotman BJ, Klein M. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 2007, 9:53-62. 1828106, 17018697.
43. Klein M, Engelberts NHJ, van der Ploeg HM, Kasteleijn-Nolst Trenité DGA, Aaronson NK, Taphoorn MJB, Baaijen H, Vandertop WP, Muller M, Postma TJ, Heimans JJ. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003, 54:514-520. 10.1002/ana.10712, 14520665.
44. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Ann N Y Acad Sci 2009, 1179:41-55. 10.1111/j.1749-6632.2009.04981.x, 19906231.
45. Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, Bentzen SM, Kuo JS, Khuntia D, Mehta MP. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010, 95:327-331. 10.1016/j.radonc.2010.02.030, 2981132, 20392503.
46. RTOG 0933 - a phase II trial of hippocampal avoidance during whole brain radiotherapy for brain metastases. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7493.